

DEPARTMENT OF JUSTICE**Drug Enforcement Administration****[Docket No. DEA-358]****Controlled Substances: Proposed Aggregate Production Quotas for 2012****AGENCY:** Drug Enforcement Administration (DEA), Department of Justice.**ACTION:** Notice with request for comment.**SUMMARY:** This notice proposes initial year 2012 aggregate production quotas for controlled substances in Schedules I and II of the Controlled Substances Act (CSA).**DATES:** Electronic comments must be submitted and written comments must be postmarked on or before November 21, 2011. Commenters should be aware that the electronic Federal Docket Management System will not accept comments after midnight Eastern Time on the last day of the comment period.**ADDRESSES:** To ensure proper handling of comments, please reference "Docket No. DEA-358" on all electronic and written correspondence. DEA encourages that all comments be submitted electronically through <http://www.regulations.gov> using the electronic comment form provided on that site. An electronic copy of this document is also available at the <http://www.regulations.gov> Web site for easy reference. Paper comments that duplicate the electronic submission are not necessary as all comments submitted to <http://www.regulations.gov> will be posted for public review and are part of the official docket record. Written comments submitted via regular or express mail should be sent to the Drug Enforcement Administration, Attention: DEA Federal Register Representative/OD, 8701 Morrisette Drive, Springfield, VA 22152.**FOR FURTHER INFORMATION CONTACT:** Rhea D. Moore, Office of Diversion Control, Drug Enforcement Administration, 8701 Morrisette Drive, Springfield, VA 22152, Telephone: (202) 307-7165.**SUPPLEMENTARY INFORMATION:****Posting of Public Comments**

Please note that all comments received are considered part of the public record and made available for public inspection online at <http://www.regulations.gov> and in the DEA's public docket. Such information includes personal identifying information (such as your name, address, etc.) voluntarily submitted by the commenter.

If you want to submit personal identifying information (such as your name, address, etc.) as part of your comment, but do not want it to be posted online or made available in the public docket, you must include the phrase "PERSONAL IDENTIFYING INFORMATION" in the first paragraph of your comment. You must also place all the personal identifying information you do not want posted online or made available in the public docket in the first paragraph of your comment and identify what information you want redacted.

If you want to submit confidential business information as part of your comment, but do not want it to be posted online or made available in the public docket, you must include the phrase "CONFIDENTIAL BUSINESS INFORMATION" in the first paragraph of your comment. You must also prominently identify confidential business information to be redacted within the comment. If a comment has so much confidential business information that it cannot be effectively redacted, all or part of that comment may not be posted online or made available in the public docket.

Personal identifying information and confidential business information identified and located as set forth above will be redacted, and the comment, in redacted form, will be posted online and placed in the DEA's public docket file. Please note that the Freedom of Information Act applies to all comments received. If you wish to inspect the agency's public docket file in person by appointment, please see the **FOR FURTHER INFORMATION CONTACT** paragraph.

Background

Section 306 of the CSA (21 U.S.C. 826) requires that the Attorney General

establish aggregate production quotas for each basic class of controlled substance listed in Schedules I and II. This responsibility has been delegated to the Administrator of the DEA by 28 CFR 0.100.

The proposed year 2012 aggregate production quotas represent those quantities of Schedule I and II controlled substances that may be produced in the United States in 2012 to provide adequate supplies of each substance for the estimated medical, scientific, research, and industrial needs of the United States, lawful export requirements, and the establishment and maintenance of reserve stocks. These quotas do not include imports of controlled substances for use in industrial processes.

In determining the proposed 2012 aggregate production quotas, the DEA has taken into account the criteria that DEA is required to consider in accordance with 21 U.S.C. 826(a) and 21 CFR 1303.11. DEA proposes the aggregate production quotas for 2012 by considering (1) total net disposal of the class by all manufacturers during the current and two preceding years; (2) trends in the national rate of net disposal of the class; (3) total actual (or estimated) inventories of the class and of all substances manufactured from the class, and trends in inventory accumulation; (4) projected demand for such class as indicated by procurement quotas requested pursuant to 21 CFR 1303.12; and (5) other factors affecting the medical, scientific, research, and industrial needs in the United States, lawful export requirements, and reserve stocks, as the Administrator finds relevant. Other factors DEA considered include product development requirements of both bulk and finished dosage form manufacturers, and other pertinent information.

The Administrator, therefore, proposes that the year 2012 aggregate production quotas for the following Schedule I and II controlled substances, expressed in grams of anhydrous acid or base, be established as follows:

Basic class—Schedule I	Proposed 2012 quotas (g)
1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200)	45
1-Butyl-3-(1-naphthoyl)indole (JWH-073)	45
1-Methyl-4-phenyl-4-propionoxypiperidine	2
1-Pentyl-3-(1-naphthoyl)indole (JWH-018)	45
2,5-Dimethoxyamphetamine	2
2,5-Dimethoxy-4-ethylamphetamine (DOET)	2
2,5-Dimethoxy-4-n-propylthiophenethylamine	2

Basic class—Schedule I	Proposed 2012 quotas (g)
3-Methylfentanyl	2
3-Methylthiofentanyl	2
3,4-Methylenedioxyamphetamine (MDA)	22
3,4-Methylenedioxy-N-ethylamphetamine (MDEA)	15
3,4-Methylenedioxymethamphetamine (MDMA)	22
3,4,5-Trimethoxyamphetamine	2
4-Bromo-2,5-dimethoxyamphetamine (DOB)	2
4-Bromo-2,5-dimethoxyphenethylamine (2-CB)	2
4-Methoxyamphetamine	77
4-Methylaminorex	2
4-Methyl-2,5-dimethoxyamphetamine (DOM)	2
5-(1,1-Dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol	68
5-(1,1-Dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol	53
5-Methoxy-3,4-methylenedioxyamphetamine	2
5-Methoxy-N,N-diisopropyltryptamine	2
Acetyl-alpha-methylfentanyl	2
Acetyldihydrocodeine	2
Acetylmethadol	2
Allylprodine	2
Alphacetylmethadol	2
Alpha-ethyltryptamine	2
Alphameprodine	2
Alphamethadol	2
Alpha-methylfentanyl	2
Alpha-methylthiofentanyl	2
Alpha-methyltryptamine (AMT)	2
Aminorex	2
Benzylmorphine	2
Betacetylmethadol	2
Beta-hydroxy-3-methylfentanyl	2
Beta-hydroxyfentanyl	2
Betameprodine	2
Betamethadol	2
Betaprodine	2
Bufotenine	3
Cathinone	4
Codeine-N-oxide	602
Diethyltryptamine	2
Difenoxin	50
Dihydromorphine	3,608,000
Dimethyltryptamine	7
Gamma-hydroxybutyric acid	29,000,000
Heroin	20
Hydromorphinol	2
Hydroxypethidine	2
Ibogaine	5
Lysergic acid diethylamide (LSD)	16
Marihuana	21,000
Mescaline	5
Methaqualone	10
Methcathinone	4
Methyldihydromorphine	2
Morphine-N-oxide	605
N-Benzylpiperazine	2
N,N-Dimethylamphetamine	2
N-Ethylamphetamine	2
N-Hydroxy-3,4-methylenedioxyamphetamine	2
Noracymethadol	2
Norlevorphanol	52
Normethadone	2
Normorphine	18
Para-fluorofentanyl	2
Phenomorphan	2
Pholcodine	2
Psilocybin	2
Psilocyn	2
Tetrahydrocannabinols	393,000
Thiofentanyl	2
Tilidine	10
Trimeperidine	2

Basic class—Schedule II	Proposed 2012 quotas (g)
1-Phenylcyclohexylamine	2
1-Piperdinocyclohexanecarbonitrile	2
4-Anilino-N-phenethyl-4-piperidine (ANPP)	1,800,000
Alfentanil	11,600
Alphaprodine	2
Amobarbital	40,007
Amphetamine (for conversion)	8,500,000
Amphetamine (for sale)	25,300,000
Cocaine	216,000
Codeine (for conversion)	65,000,000
Codeine (for sale)	39,605,000
Dextropropoxyphene	7
Dihydrocodeine	255,000
Diphenoxylate	500,000
Ecgonine	83,000
Ethylmorphine	2
Fentanyl	1,428,000
Glutethimide	2
Hydrocodone (for sale)	59,000,000
Hydromorphone	3,455,000
Isomethadone	4
Levo-alphaacetylmethadol (LAAM)	3
Levomethorphan	5
Levorphanol	3,600
Lisdexamfetamine	10,400,000
Meperidine	5,200,000
Meperidine Intermediate—A	3
Meperidine Intermediate—B	7
Meperidine Intermediate—C	3
Metazocine	5
Methadone (for sale)	20,000,000
Methadone Intermediate	26,000,000
Methamphetamine	3,130,000
[750,000 grams of levo-desoxyephedrine for use in a non-controlled, non-prescription product; 2,331,000 grams for methamphetamine mostly for conversion to a schedule III product; and 49,000 grams for methamphetamine (for sale)]	
Methylphenidate	56,000,000
Morphine (for conversion)	83,000,000
Morphine (for sale)	39,000,000
Nabilone	10,502
Noroxymorphone (for conversion)	7,200,000
Noroxymorphone (for sale)	401,000
Opium (powder)	63,000
Opium (tincture)	1,000,000
Oripavine	9,800,000
Oxycodone (for conversion)	5,600,000
Oxycodone (for sale)	98,000,000
Oxymorphone (for conversion)	12,800,000
Oxymorphone (for sale)	5,500,000
Pentobarbital	31,000,000
Phenazocine	5
Phencyclidine	24
Phenmetrazine	2
Phenylacetone	8,000,000
Racemethorphan	2
Remifentanyl	2,500
Secobarbital	336,002
Sufentanil	5,000
Tapentadol	243,000
Thebaine	116,000,000

The Administrator further proposes that aggregate production quotas for all other Schedule I and II controlled substances included in 21 CFR 1308.11 and 1308.12 be established at zero. Pursuant to 21 CFR 1303.13, upon consideration of the relevant factors, the

Administrator of the DEA may adjust the 2012 aggregate production quotas as needed.

Comments

Pursuant to 21 CFR 1303.11, any interested person may submit written

comments on or objections to these proposed determinations. Based on comments received in response to this Notice, the Administrator may hold a public hearing on one or more issues raised. In the event the Administrator decides in her sole discretion to hold

such a hearing, the Administrator will publish a notice of any such hearing in the **Federal Register**. After consideration of any comments and after a hearing, if one is held, the Administrator will publish in the **Federal Register** a final order determining the 2012 aggregate production quota for the basic class of controlled substance.

Dated: October 7, 2011.

Michele M. Leonhart,
Administrator.

[FR Doc. 2011-27283 Filed 10-20-11; 8:45 am]

BILLING CODE 4410-09-P

NATIONAL AERONAUTICS AND SPACE ADMINISTRATION

[Notice: (11-101)]

NASA Advisory Council; Audit, Finance, and Analysis Committee Meeting

AGENCY: National Aeronautics and Space Administration.

ACTION: Notice of meeting change of location.

Reference: Federal Register/Vol. 76, No. 200, Monday, October 17, 2011 (Notice 11-096, 64112).

SUMMARY: In accordance with the Federal Advisory Committee Act, Public Law 92-463, as amended, the National Aeronautics and Space Administration (NASA) announces that the meeting of the Audit, Finance and Analysis Committee of the NASA Advisory Council scheduled to be held at NASA Goddard Space Flight Center in Greenbelt, Maryland, on November 1-2, 2011, has been moved to a new location. It will now be held as follows: NASA Headquarters, Room 8D48, 300 E Street, SW., Washington, DC 20546, Tuesday, November 1, 2011, 2:00-5:15 p.m. and Wednesday, November 2, 2011, 9:00-9:55 a.m., Local Time.

FOR FURTHER INFORMATION CONTACT: Ms. Charlene Williams, Office of the Chief Financial Officer, NASA Headquarters, Washington, DC 20546, Phone: 202-358-2183.

SUPPLEMENTARY INFORMATION: The meeting will be open to the public up to the seating capacity of the room. Visitors will need to show a valid picture identification such as a driver's license to enter the NASA Headquarters building (West Lobby—Visitor Control Center), and must state that they are attending the Audit, Finance, and Analysis Committee meeting in room 8D48 before receiving an access badge. All non-U.S. citizens must fax a copy of

their passport, and print or type their name, current address, citizenship, company affiliation (if applicable) to include address, telephone number, and their title, place of birth, date of birth, U.S. visa information to include type, number, and expiration date, U.S. Social Security Number (if applicable), and place and date of entry into the U.S., fax to Charlene Williams, Executive Secretary, Audit, Finance, and Analysis Committee, FAX (202) 358-4336, by no later than October 27, 2011.

Dated: October 18, 2011.

P. Diane Rausch,
Advisory Committee Management Officer,
National Aeronautics and Space Administration.

[FR Doc. 2011-27329 Filed 10-20-11; 8:45 am]

BILLING CODE 7510-13-P

NATIONAL AERONAUTICS AND SPACE ADMINISTRATION

[Notice (11-099)]

National Space-Based Positioning, Navigation, and Timing (PNT) Advisory Board; Meeting

AGENCY: National Aeronautics and Space Administration (NASA).

ACTION: Notice of meeting.

SUMMARY: In accordance with the Federal Advisory Committee Act (Pub. L. 92-463, as amended), and the President's 2004 U.S. Space-Based Positioning, Navigation, and Timing Policy, the National Aeronautics and Space Administration announces a meeting of the National Space-Based Positioning, Navigation, and Timing Advisory Board.

DATES: Wednesday, November 9, 2011, 9 a.m. to 5 p.m.; and Thursday, November 10, 2011, 9 a.m. to 1 p.m.

ADDRESSES: The Crowne Plaza Old Town Alexandria, 901 North Fairfax, Washington Ballroom, Alexandria, VA 22314.

FOR FURTHER INFORMATION CONTACT: Mr. James J. Miller, Human Exploration and Operations Mission Directorate, National Aeronautics and Space Administration, Washington, DC 20546, (202) 358-4417.

SUPPLEMENTARY INFORMATION: The meeting will be open to the public up to the seating capacity of the room. It is imperative that the meeting be held on these dates to accommodate the scheduling priorities of the key participants. Visitors will be requested to sign a visitor's register. The agenda for the meeting includes the following topics:

- Update on U.S. Space-Based Positioning, Navigation and Timing Policy and Global Positioning System (GPS) modernization.

- Explore opportunities for enhancing the interoperability of GPS with other emerging international Global Navigation Satellite System constellation services.

- Examine emerging trends and requirements for PNT services in U.S. and international arenas through PNT Board technical assessments.

- Prioritize current and planned GPS capabilities and services while assessing future PNT architecture options.

- Review GPS Standard Positioning Service Performance Standards and effects on "non-ICD compliant" receivers in the marketplace.

- Address future challenges to PNT service providers and users such as protecting the emerging role of PNT in cyber networks, including the need for back-ups.

- Identify and respond to the latest developments on radio frequency interference from proposed Mobile Satellite Service Ancillary Terrestrial Component operations.

Dated: October 14, 2011.

P. Diane Rausch,
Advisory Committee Management Officer,
National Aeronautics and Space Administration.

[FR Doc. 2011-27256 Filed 10-20-11; 8:45 am]

BILLING CODE 7510-13-P

NATIONAL AERONAUTICS AND SPACE ADMINISTRATION

[Notice: (11-100)]

NASA Advisory Council; Meeting

AGENCY: National Aeronautics and Space Administration.

ACTION: Notice of meeting cancellation.

SUMMARY: In accordance with the Federal Advisory Committee Act, Public Law 92-463, as amended, the National Aeronautics and Space Administration announces that the meeting of the NASA Advisory Council scheduled to be held at NASA Goddard Space Flight Center in Greenbelt, Maryland, on November 3-4, 2011, has been postponed due to scheduling conflict. It will be rescheduled in the future.

FOR FURTHER INFORMATION CONTACT: Ms. Marla King, NAC Administrative Officer, National Aeronautics and Space Administration, Washington, DC 20546, 202/358-1148.